Compare BioNTech SE - ADR (BNTX) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs SoundHound AI Inc — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while SoundHound AI Inc trades at $7.35 (market cap $3.29B). The key difference: BioNTech SE - ADR is far larger — about 7.1× SoundHound AI Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | SOUN | |
|---|---|---|
Market Cap | $23.31B | $3.29B |
Sector | Health | Technology |
52-Week High | $119.34 | $21.40 |
52-Week Low | $83.89 | $5.70 |
Enterprise Value | $6.60B | $3.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
SOUN trades at $7.35, down 1.47% on the day, with a bullish technical signal from moving averages. The company reported strong revenue growth of 45% in Q2 2026 and raised its full-year outlook, driven by its OASYS platform. However, it remains unprofitable with a net income margin of -67.45% and negative cash flow from operations. Analyst sentiment is positive with a 75% buy rating and an $8.50 consensus price target.
The outlook hinges on SOUN's ability to convert rapid revenue growth into profitability. Investment opportunity lies in market leadership in voice AI and enterprise adoption via OASYS. Key risks include persistent cash burn, high valuation multiples, and execution challenges in integrating acquisitions like LivePerson.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
